CFO appointment
Cue Biopharma, Inc. appoints James Ahlers as CFO
Cue Biopharma, Inc. reported in a Form 8-K filed August 3, 2026 that James Ahlers was appointed Chief Financial Officer, effective July 30, 2026.
In the filing's words
On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026 (the “Effective Date”). In connection with his appointment as Chief Financial Officer, Mr. Ahlers will serve as the Company’s principal financial officer.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Cue Biopharma, Inc. (CUE) |
|---|---|
| Event | Appointment |
| Incoming | James Ahlers |
| Title in the filing | Chief Financial Officer |
| Effective | July 30, 2026 |
| 8-K filed | August 3, 2026 |
| Internal promotion | No |
| Prior role (per filing) | consulting Chief Financial Officer and strategic advisor to emerging life sciences companies, Danforth Advisors, LLC |
| SEC CIK | 0001645460 |
Cue Biopharma, Inc. reported this change in a Form 8-K, Item 5.02, filed August 3, 2026. The filing's own words are quoted above.
Same industry, August 2026
4Other moves filed that month at companies the roster files under SIC “Pharmaceutical Preparations”.
2 months ago· 2026-08-19DeparturePDSB
PDS Biotechnology Corporation discloses CFO departure: Lars Boesgaard
3 months ago· 2026-08-13DepartureADIL
Adial Pharmaceuticals, Inc. discloses CFO departure: Vinay Shah
3 months ago· 2026-08-13AppointmentOLMA
Olema Pharmaceuticals, Inc. appoints Jason O'Byrne as CFO
3 months ago· 2026-08-06AppointmentNATR
Nature's Sunshine Products, Inc. appoints Ruth Perkins as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about James Ahlers? Send a correction with the primary source.